Pfizer Receivables 2012-2026 | PFE
Pfizer receivables from 2012 to 2026. Receivables can be defined as the total amount of collectibles for a company
- Pfizer receivables for the quarter ending March 31, 2026 were $14.260B, a 1.32% decline year-over-year.
- Pfizer receivables for 2024 were $11.463B, a 0.89% decline from 2023.
- Pfizer receivables for 2023 were $11.566B, a 5.61% increase from 2022.
- Pfizer receivables for 2022 were $10.952B, a 4.59% decline from 2021.
|
Pfizer Annual Receivables (Millions of US $) |
|
|---|---|
| 2024 | $11,463 |
| 2023 | $11,566 |
| 2022 | $10,952 |
| 2021 | $11,479 |
| 2020 | $7,913 |
| 2019 | $6,772 |
| 2018 | $8,025 |
| 2017 | $8,221 |
| 2016 | $8,225 |
| 2015 | $8,176 |
| 2014 | $8,401 |
| 2013 | $9,357 |
| 2012 | $10,675 |
| 2011 | $13,058 |
|
Pfizer Quarterly Receivables (Millions of US $) |
|
|---|---|
| 2025-09-30 | $14,260 |
| 2025-06-30 | $12,078 |
| 2025-03-31 | $11,845 |
| 2024-12-31 | $11,463 |
| 2024-09-30 | $14,451 |
| 2024-06-30 | $11,393 |
| 2024-03-31 | $10,989 |
| 2023-12-31 | $11,566 |
| 2023-09-30 | $11,086 |
| 2023-06-30 | $10,231 |
| 2023-03-31 | $12,305 |
| 2022-12-31 | $10,952 |
| 2022-09-30 | $16,076 |
| 2022-06-30 | $15,155 |
| 2022-03-31 | $13,225 |
| 2021-12-31 | $11,479 |
| 2021-09-30 | $11,897 |
| 2021-06-30 | $10,587 |
| 2021-03-31 | $9,864 |
| 2020-12-31 | $7,913 |
| 2020-09-30 | $10,012 |
| 2020-06-30 | $9,128 |
| 2020-03-31 | $9,881 |
| 2019-12-31 | $6,772 |
| 2019-09-30 | $9,439 |
| 2019-06-30 | $9,793 |
| 2019-03-31 | $9,599 |
| 2018-12-31 | $8,025 |
| 2018-09-30 | $10,024 |
| 2018-06-30 | $9,873 |
| 2018-03-31 | $9,452 |
| 2017-12-31 | $8,221 |
| 2017-09-30 | $10,002 |
| 2017-06-30 | $9,476 |
| 2017-03-31 | $8,892 |
| 2016-12-31 | $8,225 |
| 2016-09-30 | $9,836 |
| 2016-06-30 | $9,138 |
| 2016-03-31 | $9,033 |
| 2015-12-31 | $8,176 |
| 2015-09-30 | $9,535 |
| 2015-06-30 | $8,951 |
| 2015-03-31 | $8,920 |
| 2014-12-31 | $8,401 |
| 2014-09-30 | $9,955 |
| 2014-06-30 | $10,388 |
| 2014-03-31 | $9,399 |
| 2013-12-31 | $9,357 |
| 2013-09-30 | $11,371 |
| 2013-06-30 | $11,523 |
| 2013-03-31 | $12,735 |
| 2012-12-31 | $10,675 |
| 2012-09-30 | $12,523 |
| 2012-06-30 | $12,882 |
| 2012-03-31 | $14,182 |
| 2011-12-31 | $13,058 |
| 2011-09-30 | $15,749 |
| 2011-06-30 | $15,192 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |